News stories about Concert Pharmaceuticals (NASDAQ:CNCE) have trended positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.30 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5827887686913 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Concert Pharmaceuticals Inc (CNCE) Shares Sold by Senvest Management LLC (americanbankingnews.com)
- Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018 (finance.yahoo.com)
- $8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter (americanbankingnews.com)
- Concert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per Share (americanbankingnews.com)
Several analysts have recently commented on the stock. Mizuho reaffirmed a “hold” rating and set a $23.00 price objective on shares of Concert Pharmaceuticals in a research report on Thursday, February 1st. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. BidaskClub raised shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, February 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Concert Pharmaceuticals in a research report on Friday, November 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $24.33.
In related news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of Concert Pharmaceuticals stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronald W. Barrett sold 14,156 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now owns 3,539 shares in the company, valued at $87,413.30. The disclosure for this sale can be found here. In the last three months, insiders sold 1,433,248 shares of company stock valued at $37,226,329. 10.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Positive Press Coverage Somewhat Unlikely to Impact Concert Pharmaceuticals (CNCE) Stock Price” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3223561/positive-press-coverage-somewhat-unlikely-to-impact-concert-pharmaceuticals-cnce-stock-price.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.